Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: Results of a phase Ib study

Jesus Berdeja  
Sarah Cannon Research Institute

Sundar Jagannath  
Mount Sinai Hospital

Jeffrey Zonder  
Wayne State University

Ashraf Badros  
University of Maryland at Baltimore

Jonathan L. Kaufman  
Emory University

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Berdeja, Jesus; Jagannath, Sundar; Zonder, Jeffrey; Badros, Ashraf; Kaufman, Jonathan L.; Manges, Robert; Gupta, Manish; Tendolkar, Amol; Lynch, Mark; Bleickardt, Eric; Paliwal, Prashni; and Vij, Ravi, "Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: Results of a phase Ib study." Clinical lymphoma myeloma and leukemia. 16, 3. 129-138. (2016).  
https://digitalcommons.wustl.edu/open_access_pubs/5593

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Jesus Berdeja, Sundar Jagannath, Jeffrey Zonder, Ashraf Badros, Jonathan L. Kaufman, Robert Manges, Manish Gupta, Amol Tendolkar, Mark Lynch, Eric Bleickardt, Prashni Paliwal, and Ravi Vij
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

Jesus Berdeja,1 Sundar Jagannath,2 Jeffrey Zonder,3 Ashraf Badros,4 Jonathan L. Kaufman,5 Robert Manges,6 Manish Gupta,7 Amol Tendolkar,7 Mark Lynch,8 Eric Bleickardt,8 Prashni Paliwal,8 Ravi Vij9

Abstract
Renal impairment is associated with a poor prognosis in patients with multiple myeloma (MM), and more treatment options are needed. The pharmacokinetics of elotuzumab, a humanized IgG1 monoclonal antibody, combined with lenalidomide and dexamethasone, is not significantly different between patients with MM with and without renal impairment, suggesting that elotuzumab might be administered without dose adjustment for renal function.

Introduction: The present study evaluated the pharmacokinetics and safety of elotuzumab, a humanized IgG1 monoclonal antibody against signaling lymphocyte activation molecule-F7, combined with lenalidomide and dexamethasone, in patients with multiple myeloma (MM) and renal impairment. Patients and Methods: Patients with MM and normal renal function (NRF) (creatinine clearance [CrCl] ≥ 90 mL/min), severe renal impairment (SRI) (CrCl < 30 mL/min, not requiring dialysis), or end-stage renal disease (ESRD) (requiring dialysis) were enrolled in this open-label, phase Ib study. Elotuzumab (10 mg/kg), lenalidomide (5-25 mg), and dexamethasone (40 mg) were administered in 28-day cycles until disease progression or unacceptable toxicity developed. The primary endpoint was single-dose elotuzumab pharmacokinetics. Results: A total of 26 patients (median age, 63 years) were treated (NRF, n = 8; SRI, n = 9; ESRD, n = 9). The median baseline CrCl was 105 mL/min (range, 84-146 mL/min) for those with NRF and 26 mL/min (range, 15-33 mL/min) for those with SRI. Twenty-three patients (89%) had received previous therapy (median, 2 regimens; range, 1-7). Treatment was discontinued in 6 patients with NRF, 4 with SRI, and 5 with ESRD, primarily because of disease progression. The mean elotuzumab serum concentrations were comparable across groups (n = 23). No statistically significant differences were observed in the maximum observed serum concentration, area under the concentration-time curve from time 0 to the last quantifiable serum concentration, or area under the concentration-time curve from time 0 to infinity when the SRI and ESRD groups were compared with the NRF group (P > .05). All patients had 1 adverse event (AE). Of the 8 patients with NRF, 9 with SRI, and 9 with ESRD, 7, 8, and 7 experienced grade 3 to 4 AEs. The overall response rates were 75% in the NRF, 67% in the SRI, and 56% in the ESRD groups. Conclusion: The results of the present study support the use of elotuzumab for the treatment of patients with MM and renal dysfunction without dose adjustment.

Keywords: Creatinine clearance, End-stage renal disease, Glomerular filtration rate, Monoclonal antibody, SLAMF7

1Sarah Cannon Research Institute, Nashville, TN
2Mount Sinai Hospital, New York, NY
3Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI
4University of Maryland, Baltimore, MD
5Winship Cancer Institute, Emory University, Atlanta, GA
6Investigative Clinical Research of Indiana, Indianapolis, IN
7Bristol-Myers Squibb, Princeton, NJ
8Bristol-Myers Squibb, Wallingford, CT
9Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO

Submitted: Sep 22, 2015; Revised: Nov 18, 2015; Accepted: Dec 15, 2015; Epub: Dec 21, 2015

Address for correspondence: Jesus Berdeja, MD, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 412, Nashville, TN 37203
E-mail contact: jberdeja@tnonc.com

Clinical Lymphoma, Myeloma & Leukemia, Vol. 16, No. 3, 129-38 © 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Clinical Lymphoma, Myeloma & Leukemia, March 2016
Introduction

Renal impairment is a common comorbidity associated with multiple myeloma (MM), with ≤ 50% of patients affected during the course of their disease and 10% requiring dialysis. In most patients with MM, renal impairment is due to the overproduction of monoclonal free light chains, which causes cast nephropathy (also known as myeloma kidney). Renal impairment is associated with poor outcomes and is an important prognostic factor in MM. The median survival of patients with MM and renal failure has been reported to be 19.5 months compared with 40.4 months for patients without renal failure. Furthermore, the reversal of renal impairment in patients with MM has been associated with an improved prognosis and longer overall survival (OS).

Advances in therapy, including the use of immunomodulatory drugs (IMiDs) (eg, lenalidomide, thalidomide, and pomalidomide), proteasome inhibitors (eg, bortezomib), and autologous stem cell transplantation, have greatly improved the life expectancy of patients with MM, including those with impaired renal function. Continuous lenalidomide and dexamethasone in newly diagnosed patients has demonstrated a median progression-free survival (PFS) of 25.5 months and an OS at 4 years of 59%. The 1- and 3-year PFS have also been shown to be superior in patients newly treated with lenalidomide and dexamethasone compared with patients treated with placebo and dexamethasone (78% and 52% vs. 52% and 32%, respectively). Furthermore, the overall response and very good partial response (VGPR) rates were 78% and 63% with lenalidomide and dexamethasone and 48% and 16% with placebo and dexamethasone, respectively. An overall response rate (ORR) of 64% was reported for patients with MM and impaired renal function treated with lenalidomide combined with high-dose dexamethasone, with improvements in renal function reported in 72% of patients with MM and mild-to-moderate renal impairment. However, because lenalidomide is excrated primarily through the kidney, the half-life of the drug increases and drug clearance decreases linearly with the severity of kidney impairment. Thus, dose adjustments are required according to the creatinine clearance (CrCl).

Dimopoulos et al reported that a dose reduction of lenalidomide or interruption because of adverse events (AEs) was necessary in 22% of patients with MM and mild or no renal impairment, 40% of patients with MM and moderate renal impairment, and 38% of patients with MM and severe renal impairment (SRI). Furthermore, patients with SRI treated with lenalidomide plus dexamethasone have been shown to have shorter OS compared with patients with mild or no renal impairment. Also, the response rate has been shown to decline with severity of renal impairment. To improve the outcome of patients with MM and renal impairment, new alternative efficacious and well-tolerated treatment options are necessary.

Elotuzumab is a humanized IgG1 immunostimulatory monoclonal antibody targeted against signaling lymphocyte activation molecule-F7 (SLAMF7; also referred to as CS1), a glycoprotein expressed on myeloma and natural killer cells but not on normal tissues. Through both direct activation and engagement of natural killer cells, elotuzumab selectively targets and kills SLAMF7-expressing myeloma cells with minimal effects on normal tissue. A phase I study assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of elotuzumab (dose range, 0.5-20 mg/kg every 2 weeks) demonstrated that elotuzumab was generally well tolerated at doses sufficient to achieve consistent SLAMF7 saturation (10 or 20 mg/kg). No objective responses were seen in this single-agent phase I trial. However, 27% of patients achieved disease stabilization. A phase Ib-II study investigating the safety and efficacy of elotuzumab combined with lenalidomide and dexamethasone demonstrated an ORR of 82% in phase Ib, which compared favorably with the historical response rate of 60% with lenalidomide and dexamethasone alone in patients with relapsed or refractory MM (RRMM). Moreover, in phase II of the study, an ORR of 84% and PFS of 29 months were observed, and treatment was generally well tolerated, with no dose-limiting toxicities reported. In the randomized, open-label phase III ELOQUENT-2 study, patients treated with elotuzumab plus lenalidomide and dexamethasone demonstrated an ORR of 79% compared with an ORR of 66% for patients treated with lenalidomide and dexamethasone. A median PFS of 19.4 months versus 14.9 months was observed in the elotuzumab arm and lenalidomide/dexamethasone arm, respectively. Bortezomib significantly enhanced elotuzumab activity in a preclinical model, and a phase II, randomized, proof-of-concept study demonstrated a median PFS of 9.7 months for patients receiving elotuzumab combined with bortezomib and dexamethasone versus 6.9 months for patients receiving bortezomib and dexamethasone.

To determine whether elotuzumab could be safely administered with lenalidomide and dexamethasone in patients with renal impairment, the present phase Ib study was conducted to evaluate the PK and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with MM and various levels of renal function (normal renal function [NRF], SRI, and end-stage renal disease [ESRD]).

Patients and Methods

Study Design

The present study was a phase Ib, multicenter, open-label study (ClinicalTrials.gov identifier, NCT01393964) of elotuzumab combined with lenalidomide and dexamethasone in patients with MM and NRF (CrCl ≥ 90 mL/min), SRI (CrCl < 30 mL/min and not requiring dialysis), and ESRD (requiring dialysis). The present study was conducted in accordance with Good Clinical Practice, as defined by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, and the ethical principles of the European Union Directive and the US Code of Federal Regulations. All patients (or, where necessary, legal guardians) provided written, informed consent before participation. The present study was conducted at 8 sites across the United States, with patients enrolled from January 2012 to October 2013. The cutoff for data analysis was June 30, 2014.

Treatment was administered in 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. The overall study design is shown in Figure 1. During each cycle, elotuzumab...
Inclusion and Exclusion Criteria

All patients met the following criteria: age ≥ 18 years; documented evidence of symptomatic newly diagnosed MM or RRMM; NRF, SRI, or ESRD; Eastern Cooperative Oncology Group performance status of ≤ 2; evaluable or measurable disease as defined by the IMWG.

Previous lenalidomide treatment was permitted if patients had not discontinued lenalidomide because of grade ≥ 3 treatment-related AEs.

The key exclusion criteria included previous or concurrent malignancy, monoclonal gammopathy of unknown significance, Waldenström’s macroglobulinemia, or smoldering myeloma; active plasma cell leukemia; acute renal failure owing to readily reversible causes; significant cardiac disease; and previous therapy with elotuzumab or any IMiD (including pomalidomide), except for previous thalidomide or lenalidomide (as defined in the inclusion criteria).

Study Population

The safety population included all patients who had received ≥ 1 dose of the study treatment. The PK population included all patients who had received ≥ 1 dose of elotuzumab and had stable renal function, determined by 2 creatinine measurements ≥ 24 hours apart and within a 14-day screening period. To ensure stable renal function, patients with a significant change in renal function during cycle 1 (ie, level of renal impairment improved or worsened in relation to enrollment category) were excluded.

Study Objectives

The primary objective was to assess the effect of SRI and ESRD on the single-dose PK of elotuzumab. The secondary objective was to assess the safety of elotuzumab combined with lenalidomide and dexamethasone in patients with MM, with or without SRI or ESRD. Other exploratory objectives included the efficacy of elotuzumab combined with lenalidomide and dexamethasone in patients with SRI or ESRD and assessment of the degree and rapidity of renal function improvement in patients with SRI.

Assessments

During cycle 1, blood samples were collected before and at 10 points after elotuzumab administration to evaluate elotuzumab single-dose PK. The PK assessments included the maximum observed serum concentration (C_{max}), area under the concentration–time curve from time 0 to the last quantifiable serum concentration [AUC_{0–T}], area under the concentration–time curve from time 0 to infinity [AUC_{INF}], and total body clearance (CLT). Additional samples were collected from patients with ESRD immediately before and after dialysis. Elotuzumab serum concentrations were assessed using a validated enzyme-linked
immunosorbent assay. Throughout the study, blood samples were collected before elotuzumab administration for the detection of antidrug antibodies and assessed using a validated enzyme-linked immunosorbent assay. The first sample was collected on day 1 of cycle 1 and on day 1 of all subsequent cycles.

AE data were gathered through spontaneous reporting or open-ended questioning, examination, or evaluation. All serious adverse events (SAEs) that occurred within 60 days of discontinuation of dosing or within 30 days of the last visit were reported.

For the efficacy assessments, the ORR (defined as a partial response or better) was evaluated every 4 weeks from the date of the first dose of the study drug using the IMWG response assessment criteria. The criteria proposed by Dimopoulos et al25 were used to define the degree of renal response in the SRI group. A minor renal response was defined as sustained improvement of baseline CrCl of $< 15$ mL/min to 15 to 29 mL/min or improvement of the baseline CrCl of 15 to 29 mL/min to 30 to 59 mL/min.25

**Statistical Analysis**

PK parameters were determined using WinNonlin, version 5.2 or higher (Pharsight Corporation, Mountain View, CA). Analysis of variance was performed on log-transformed $\text{AUC}_{(0-\infty)}$, $\text{AUC}_{(\text{INF})}$, and $C_{\text{max}}$ with the renal function group as a fixed effect to assess the effect of renal impairment on elotuzumab PK.

**Results**

A total of 35 patients were enrolled. Of the 35 patients, 26 (74%) were treated with elotuzumab combined with lenalidomide and dexamethasone. However, 9 (26%) did not receive treatment because they no longer met the study criteria (n = 8) or at the decision of the investigator (n = 1; Figure 2). At the data cutoff point, 11 patients (42%) were still receiving treatment (2 with NRF [25%], 5 with SRI [56%], and 4 with ESRD [44%]), and 15 (58%) had discontinued the study. The most common reason for discontinuation was disease progression (Figure 2). One patient in the NRF group was withdrawn from the study because of study drug toxicity (infusion-related reaction).
The baseline demographics are listed in Table 1. The patients in the SRI group were slightly older, and a greater proportion of patients in the ESRD group were black or African American and had stage III disease (according to the International Staging System). A total of 23 patients (89%) had received previous therapy for MM, which included bortezomib (81%), thalidomide (42%), and lenalidomide (35%). Three patients (12%) had newly diagnosed MM, and 21 (81%) had RRMM. A greater proportion of patients in the ESRD group had disease refractory to their most recent line of therapy (NRF, 38%; SRI, 22%; and ESRD, 56%).

The patients received a median of 6.5 (range, 2-23), 16.0 (range, 2-25), and 9.0 (range, 2-25) treatment cycles in the NRF, SRI, and ESRD groups, respectively. The median duration of treatment for the NRF, SRI, and ESRD groups was 5.4 months (range, 1.0-21.7 months), 15.5 months (range, 1.4-23.7 months), and 8.1 months (range, 1.0-23.0 months) for elotuzumab; 5.7 months (range, 0.5-21.8 months), 7.2 months (range, 0.3-21.6 months), and 8.6 months (range, 0.7-22.8 months) for lenalidomide; and 5.6 months (range, 1.0-21.7 months), 15.5 months (range, 1.4-23.8 months), and 8.1 months (range, 1.0-23.1 months) for dexamethasone, respectively. The median duration of treatment was lower for the NRF group than for the SRI and ESRD groups because patients discontinued treatment < 6 months from study initiation owing to infusion reaction in 1, physician’s request for 2, and progressive disease after an initial response of stable disease and a partial response in 1 each.

With regard to the relative dose intensity, 5 patients (63%) in the NRF group, 6 (67%) in the SRI group, and 5 (56%) in the ESRD group received ≥ 90% of the planned elotuzumab dose. Two patients in each group (NRF, 25%; SRI, 22%; and ESRD 22%) received 80% to < 90% of the planned elotuzumab doses. Two patients (25%) in the NRF group, 4 (44%) in the SRI group, and 3 (33%) in the ESRD group received ≥ 90% of the planned lenalidomide dose. Two patients (25%) in the NRF group, 4 (44%) in the SRI group, and 1 (11%) in the ESRD group received ≥ 90% of the planned dexamethasone dose.

**Elotuzumab PK**

The mean elotuzumab serum concentration profiles were comparable across all treatment groups after single-dose administration in cycle 1 (Figure 3A). No statistically significant differences were observed in $C_{\text{max}}$, $AUC_{\text{0-72h}}$, or $AUC_{\text{INF}}$ between the SRI and ESRD groups and the NRF group (Table 2; Figure 3B and C).

Minor differences in $AUC_{\text{INF}}$ were observed among the groups. A trend was seen toward a greater $AUC_{\text{INF}}$ in the SRI and ESRD groups than in the NRF group, although these differences were not statistically significant. In an exploratory analysis, relatively smaller differences in $AUC_{\text{INF}}$ were observed among the 3 groups after the exclusion of 3 patients (2 in the NRF group and 1 in the ESRD group) who had developed antidrug antibodies on day 1 of cycle 2. The mean $AUC_{\text{INF}}$ after exclusion of these 3 patients was 53,062, 60,255, and 56,093 μg.h/mL for the NRF, SRI, and ESRD groups, respectively. The mean elotuzumab CLT values were similar among the 3 groups (Table 2).
Elotuzumab Pharmacokinetics (PK) Values Stratified by Renal Function:

(A) Elotuzumab Serum Concentration Profiles Over Time From Initial Elotuzumab Dose; (B) Maximum Observed Serum Concentration (C_max); (C) Area Under the Concentration–Time Curve From Time 0 to Infinity [AUC(INF)].

Three Patients Were Excluded From the PK Summary Statistics Because of a Dosing Error (End-Stage Renal Disease [ESRD] Group, n = 1), Estimated Glomerular Filtration Rate (eGFR) Outside the Value Limit Range (Severe Renal Impairment [SRI] Group, n = 1), and Limited Samples or Biologically Implausible Time Corresponding to C_max (T_max) at 672 Hours (SRI Group, n = 1).

*Mean 48-hour Dialysis Values Were Excluded in 1 Patient*

**Figure 3**

Abbreviations: NRF = normal renal function; SD = standard deviation.
patients in the NRF, SRI, and ESRD groups, respectively. A VGPR or better was observed in 3 (38%), 5 (56%), and 1 (11%) observed in 2 patients (22%) in the SRI group (Table 4). These relapsed MM. No patient achieved a complete or partial renal occurred in 1 patient with newly diagnosed MM and 1 patient with

\[ eGFR \] under the concentration

\[ C_{\text{max}} \]

\[ \text{AUC}_{(0-\infty)} \]

\[ \text{AUC}_{(0-t)} \]

\[ \text{CLT} \]

\[ \text{CV} \]

\[ \text{SI} \]

\[ \text{TKA} \]

\[ \text{AUC}_{(0-\infty)} \]

\[ \text{AUC}_{(0-t)} \]

\[ \text{CLT} \]

\[ \text{CV} \]

\[ \text{SI} \]

\[ \text{TKA} \]

\[ \text{AUC}_{(0-\infty)} \]

\[ \text{AUC}_{(0-t)} \]

\[ \text{CLT} \]

\[ \text{CV} \]

\[ \text{SI} \]

\[ \text{TKA} \]

\[ \text{AUC}_{(0-\infty)} \]

\[ \text{AUC}_{(0-t)} \]

\[ \text{CLT} \]

\[ \text{CV} \]

\[ \text{SI} \]

\[ \text{TKA} \]

Abbreviations: AUC(\(0_{-1}\)) = area under the concentration–time curve from time 0 to the last quantifiable serum concentration (calculated by log- and linear-trapezoidal summations); AUC(INF) = area under the concentration—time curve from time 0 to infinity; CI = confidence interval; CLT = total body clearance; Cmax = maximum observed serum concentration; CV = coefficient of variation; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; NRF = normal renal function; PK = pharmacokinetics; SRI = severe renal impairment; Tmax = time corresponding to Cmax.

\footnote{Three patients were excluded from the PK summary statistics because of a dosing error (ESRD group, n = 1), being outside the range of eGFR value limits (SRI group, n = 1), and having limited samples/biologically implausible \(T_{\text{max}}\) at 672 hours (SRI group, n = 1).}

\section*{Safety}

All patients experienced ≥ 1 AE. A summary of AEs occurring in ≥ 3 patients in any 1 study group is provided in Table 3. Fatigue, diarrhea, back pain, constipation, and anemia were the most frequently reported AEs (Table 3). Overall, 3 of 26 patients (12%) experienced grade 2 infusion reactions (1 in the NRF group and 2 in the ESRD group).

AEs led to treatment discontinuation in 4 patients (1 in the NRF group [13%] and 3 in the SRI group [33%]). In the NRF group, discontinuation was because of an infusion-related reaction in 1 patient. In the SRI group, discontinuation was because of a soft tissue infection, increased blood creatinine level and psychiatric disorder (agitation), and a skin and subcutaneous tissue disorder (drug eruption) in 1 patient each. The AEs leading to discontinuation were grade 2 and 3 in severity and were considered to be related to study treatment, except for the elevation in the blood creatinine level.

SAEs were reported in 3 patients (38%) in the NRF group (all grade 3 or 4), 5 (56%) in the SRI group (grade 3 or 4 in 3 [33%]), and 7 (78%) in the ESRD group (grade 3 or 4 in 6 [67%]). Pneumonia (NRF group, n = 1; ESRD group, n = 1) and upper respiratory tract infection (SRI group, n = 1; ESRD group, n = 1) were the most common grade 3 and 4 SAEs. No deaths occurred.

\section*{Efficacy}

Elotuzumab combined with lenalidomide and dexamethasone resulted in overall responses in 6 (75%), 6 (67%), and 5 (56%) patients in the NRF, SRI, and ESRD groups, respectively (Table 4). A VGPR or better was observed in 3 (38%), 5 (56%), and 1 (11%) patients in the NRF, SRI, and ESRD groups, respectively.

A minor renal response, based on the estimated CrCl values, was observed in 2 patients (22%) in the SRI group (Table 4). These occurred in 1 patient with newly diagnosed MM and 1 patient with relapsed MM. No patient achieved a complete or partial renal response across all groups.

\section*{Discussion}

The findings from the present phase 1b study indicate that renal dysfunction (SRI or ESRD) does not significantly affect elotuzumab PK when administered in combination with lenalidomide and dexamethasone. These data suggest that elotuzumab 10 mg/kg, combined with lenalidomide and dexamethasone, can be administered safely to patients with MM and SRI or ESRD without the need to adjust the dose of elotuzumab according to renal function. A trend toward a greater AUC(INF) was observed in patients with renal dysfunction compared with patients with NRF. However, slight differences in elotuzumab PK exposure seem unlikely to affect clinical efficacy. The presence of antidrug antibodies can affect the PK of biologic compounds. The exclusion of 3 patients positive for antidrug antibodies resulted in a smaller difference in the AUC(INF) among the 3 patient cohorts; however, additional investigation would be required to confirm the effect of antidrug antibodies on the systemic clearance of elotuzumab. Furthermore, based on PK analyses performed in 375 patients across elotuzumab trials, no effect on the glomerular filtration rate (range, 4.58-124 mL/min/1.73 m²) has been observed after elotuzumab administration (Bristol-Myers Squibb; data on file). The absence of a relationship between renal function and elotuzumab PK is consistent with renal physiology, because the large size of elotuzumab (approximately 144 kDa) is expected to prevent it from being filtered through the glomerulus and eliminated by the kidney. The mean serum elotuzumab concentrations in the pre- and postdialysis blood samples were comparable, demonstrating that elotuzumab is not likely to be extracted to a significant extent in the dialysate.

The tolerability of elotuzumab combined with lenalidomide and dexamethasone across all classes of renal function is consistent with what has been previously described for lenalidomide plus dexamethasone alone. Treatment discontinuation in the present study most commonly resulted from disease progression, with AEs leading to treatment discontinuation in 1 patient with NRF and 3 patients with SRI. Moreover, grade 2 infusion reactions were only experienced by 3 patients: 1 in the NRF group and 2 in the ESRD group, suggesting that the rate of infusion-related reactions did not appear increased in patients with compromised renal function.

Efficacy was evaluated in an exploratory manner owing to the small sample size in the present study. However, the ORR in the NRF group was consistent with that previously reported for elotuzumab combined with lenalidomide and dexamethasone. As reported in other studies of patients with renal impairment, ORR was progressively lower for patients with SRI and ESRD. However, a VGPR or better was observed in ≥ 1 patient across all groups. Furthermore, a minor improvement in renal function

Table 2 Elotuzumab PK Parameters

<table>
<thead>
<tr>
<th>Renal Function Group</th>
<th>(\text{C}_{\text{max}}) (µg/mL)</th>
<th>\text{AUC}_{(0-\infty)}) (µg.h/mL)</th>
<th>\text{AUC}_{(0-t)}) (µg.h/mL)</th>
<th>\text{CLT}) (mL/h/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRF</td>
<td>217 (192-245; n = 8)</td>
<td>39,559 (32,635-47,953; n = 8)</td>
<td>46,401 (46,221-59,442; n = 8)</td>
<td>0.22 (46; n = 8)</td>
</tr>
<tr>
<td>SRI</td>
<td>226 (188-257; n = 7)</td>
<td>50,080 (40,769-61,518; n = 7)</td>
<td>60,225 (46,238-78,522; n = 7)</td>
<td>0.17 (28; n = 7)</td>
</tr>
<tr>
<td>ESRD</td>
<td>218 (193-246; n = 8)</td>
<td>45,937 (37,896-55,684; n = 8)</td>
<td>51,227 (39,310-66,756; n = 8)</td>
<td>0.20 (64; n = 8)</td>
</tr>
<tr>
<td>SRI vs. NRF (%)</td>
<td>104 (87-125; (P = .704))</td>
<td>127 (96-168; (P = .164))</td>
<td>130 (80-187; (P = .228))</td>
<td>NA</td>
</tr>
<tr>
<td>ESRD vs. NRF (%)</td>
<td>100 (85-119; (P = .965))</td>
<td>116 (89-152; (P = .355))</td>
<td>110 (77-159; (P = .642))</td>
<td>NA</td>
</tr>
</tbody>
</table>

Clinical Lymphoma, Myeloma & Leukemia March 2016

Jesus Berdeja et al
## Table 3  Adverse Events in ≥ 3 More Patients in Any Study Group

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>NRF (n = 8)</th>
<th></th>
<th>SRI (n = 9)</th>
<th></th>
<th>ESRD (n = 9)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Grade</td>
<td>Grade 3-4</td>
<td>Any Grade</td>
<td>Grade 3-4</td>
<td>Any Grade</td>
<td>Grade 3-4</td>
</tr>
<tr>
<td>Total patients with AE</td>
<td>8 (100)</td>
<td>7 (88)</td>
<td>9 (100)</td>
<td>8 (89)</td>
<td>9 (100)</td>
<td>7 (78)</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>8 (100)</td>
<td>1 (13)</td>
<td>7 (78)</td>
<td>1 (11)</td>
<td>5 (56)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Back pain</td>
<td>3 (38)</td>
<td>0</td>
<td>3 (33)</td>
<td>1 (11)</td>
<td>4 (44)</td>
<td>0</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>3 (38)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>7 (88)</td>
<td>0</td>
<td>7 (78)</td>
<td>1 (11)</td>
<td>7 (78)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Constipation</td>
<td>6 (75)</td>
<td>0</td>
<td>3 (33)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2 (25)</td>
<td>0</td>
<td>5 (56)</td>
<td>1 (11)</td>
<td>4 (44)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (25)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
<td>3 (33)</td>
<td>0</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>1 (13)</td>
<td>0</td>
<td>4 (44)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
</tr>
<tr>
<td>General disorders and administration-site conditions</td>
<td>7 (88)</td>
<td>2 (25)</td>
<td>7 (78)</td>
<td>0</td>
<td>9 (100)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>6 (75)</td>
<td>2 (25)</td>
<td>4 (44)</td>
<td>0</td>
<td>6 (67)</td>
<td>0</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>4 (50)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
<td>4 (44)</td>
<td>0</td>
</tr>
<tr>
<td>Malaise</td>
<td>3 (38)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>1 (13)</td>
<td>0</td>
<td>4 (44)</td>
<td>0</td>
<td>4 (44)</td>
<td>0</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>6 (75)</td>
<td>4 (50)</td>
<td>6 (67)</td>
<td>4 (44)</td>
<td>6 (67)</td>
<td>4 (44)</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>3 (38)</td>
<td>2 (25)</td>
<td>1 (11)</td>
<td>1 (11)</td>
<td>1 (11)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Anemia</td>
<td>2 (25)</td>
<td>0</td>
<td>5 (56)</td>
<td>2 (22)</td>
<td>3 (33)</td>
<td>0</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>1 (13)</td>
<td>0</td>
<td>4 (44)</td>
<td>1 (11)</td>
<td>3 (33)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>6 (75)</td>
<td>2 (25)</td>
<td>6 (67)</td>
<td>1 (11)</td>
<td>4 (44)</td>
<td>3 (33)</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>6 (75)</td>
<td>0</td>
<td>6 (67)</td>
<td>1 (11)</td>
<td>4 (44)</td>
<td>0</td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>4 (50)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>2 (25)</td>
<td>0</td>
<td>4 (44)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
</tr>
<tr>
<td>Pruritus</td>
<td>1 (13)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3 (33)</td>
<td>0</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>5 (63)</td>
<td>2 (25)</td>
<td>7 (78)</td>
<td>3 (33)</td>
<td>6 (67)</td>
<td>3 (33)</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>3 (38)</td>
<td>1 (13)</td>
<td>3 (33)</td>
<td>2 (22)</td>
<td>2 (22)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>1 (13)</td>
<td>0</td>
<td>3 (33)</td>
<td>1 (11)</td>
<td>3 (33)</td>
<td>0</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>0</td>
<td>0</td>
<td>2 (22)</td>
<td>0</td>
<td>3 (33)</td>
<td>0</td>
</tr>
<tr>
<td>Hypocalcemia</td>
<td>0</td>
<td>0</td>
<td>3 (33)</td>
<td>0</td>
<td>3 (33)</td>
<td>2 (22)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>5 (63)</td>
<td>0</td>
<td>7 (78)</td>
<td>4 (44)</td>
<td>4 (44)</td>
<td>0</td>
</tr>
<tr>
<td>Periaphalic neuropathy</td>
<td>2 (25)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
<td>3 (33)</td>
<td>0</td>
</tr>
<tr>
<td>Syncope</td>
<td>0</td>
<td>0</td>
<td>4 (44)</td>
<td>4 (44)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>5 (63)</td>
<td>0</td>
<td>2 (22)</td>
<td>0</td>
<td>3 (33)</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory, thoracic, and mediastinal disorders</td>
<td>5 (63)</td>
<td>2 (25)</td>
<td>5 (56)</td>
<td>0</td>
<td>3 (33)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Cough</td>
<td>4 (50)</td>
<td>0</td>
<td>2 (22)</td>
<td>0</td>
<td>1 (11)</td>
<td>0</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>3 (38)</td>
<td>1 (13)</td>
<td>2 (22)</td>
<td>0</td>
<td>2 (22)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>4 (50)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (22)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>3 (38)</td>
<td>0</td>
<td>2 (22)</td>
<td>1 (11)</td>
<td>1 (11)</td>
<td>0</td>
</tr>
<tr>
<td>Investigations</td>
<td>2 (25)</td>
<td>0</td>
<td>7 (78)</td>
<td>2 (22)</td>
<td>3 (33)</td>
<td>2 (22)</td>
</tr>
<tr>
<td>Increased blood creatinine</td>
<td>0</td>
<td>0</td>
<td>5 (56)</td>
<td>1 (11)</td>
<td>1 (11)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Injury, poisoning, and procedural complications</td>
<td>1 (13)</td>
<td>0</td>
<td>4 (44)</td>
<td>0</td>
<td>2 (22)</td>
<td>0</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>1 (13)</td>
<td>0</td>
<td>3 (33)</td>
<td>1 (11)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>1 (13)</td>
<td>0</td>
<td>4 (44)</td>
<td>3 (33)</td>
<td>2 (22)</td>
<td>1 (11)</td>
</tr>
</tbody>
</table>

Data presented as n (%).

Abbreviations: AE = adverse event; ESRD = end-stage renal disease; NRF = normal renal function; SRI = severe renal impairment.

*No grade 5 events occurred.
was observed in 2 patients with SRI, 1 of whom had relapsed disease. The ORRs in the present study compared favorably with previously published rates for lenalidomide and dexamethasone (present study, 75%, 67%, and 56% for NRF, SRI, and ESRD, respectively, compared with 67%, 60%, and 49% for patients with NRF, SRI, and moderate/severe renal function, respectively, for lenalidomide and dexamethasone). However, the small number of patients in the present study precluded any definitive comparison. In a large randomized trial, the addition of elotuzumab to lenalidomide and dexamethasone improved the overall response rates by 13% compared with lenalidomide and dexamethasone alone, an incremental benefit similar to that seen in the present study. Together, these findings support the feasibility of using elotuzumab combined with lenalidomide and dexamethasone in patients with MM and renal impairment and demonstrate that dose adjustments for elotuzumab are not required in this patient population.

Conclusion

The results of the present study support the use of elotuzumab without dose adjustment for the treatment of patients with MM and renal dysfunction. Elotuzumab combined with lenalidomide and dexamethasone was tolerated and efficacious for the treatment of patients with MM and renal dysfunction, including ESRD, and might be a new therapy option for this patient population. Ongoing phase III studies are investigating the efficacy of elotuzumab combined with lenalidomide and dexamethasone in patients with RRMM (ELOQUENT-2 study; ClinicalTrials.gov identifier, NCT01239797) or newly diagnosed or previously untreated MM (ELOQUENT-1 study; ClinicalTrials.gov identifier, NCT01335399).

Clinical Practice Points

- New treatment options are required for the treatment of patients with MM and renal impairment.
- Elotuzumab, a humanized IgG1 monoclonal antibody targeted against SLAMF7, in combination with lenalidomide and dexamethasone, may be used without elotuzumab dose adjustment (but with a lenalidomide dose adjustment) for renal function in patients with MM.
- Renal function does not significantly affect the PK of elotuzumab when administered with lenalidomide and dexamethasone.
- Elotuzumab, combined with lenalidomide and dexamethasone, is well tolerated in patients with MM, regardless of their renal function.
- Elotuzumab, combined with lenalidomide and dexamethasone, can be a promising new therapy for the treatment of patients with MM and renal dysfunction.

References